Special Issue "Targeted Protein Degradation: From Chemical Biology to Drug Discovery"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: 31 March 2020.

Special Issue Editors

Dr. Mikihiko Naito
E-Mail Website
Guest Editor
Chief, Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
Interests: Protein Degradation; Ubiquitin; Proteasome; Deubiquitylating Enzyme; IAP; Cancer
Dr. Yosuke Demizu
E-Mail Website
Guest Editor
Chief, Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501, Japan
Interests: Peptide; Foldamer; Non-proteinogenic Amino Acid; Protein–protein Interaction

Special Issue Information

Dear Colleagues,

Protein degradation induced by small molecules has been attracting great attention recently as a novel modality for drug development and as a novel method for basic research in chemical biology. This technology hijacks the cellular ubiquitin-proteasome system to induce protein degradation, as demonstrated by chimeric molecules (PROTACs, SNIPERs), small E3 modulators (thalidomides, sulfonamides), SERD (fulvestrant), etc.. Probably, this technology could be extended to the manipulation of other cellular events involving ubiquitin and, further, to other post translational modification systems in the future.

To explore the future possibilities of this novel technology, authors are invited to submit original and review articles on any aspect of the chemical compounds and methods capable of regulating protein degradation and the cellular ubiquitin system, including, but not limited to, protein degraders, protein degradation systems,  modifiers of the ubiquitin system, etc. The collection of manuscripts will be published as a Special Issue of the journal Pharmaceuticals.

Dr. Mikihiko Naito
Dr. Yosuke Demizu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PROTACs
  • SNIPERs
  • E3 Modulators
  • Protein Degradation
  • Ubiquitin
  • Deubiquitylating enzymes

Published Papers

This special issue is now open for submission.
Back to TopTop